Selenium supplementation for polycystic ovary syndrome: a meta-analysis of randomized controlled trials.

The efficacy of selenium supplementation was elusive for polycystic ovary syndrome. This meta-analysis aimed to explore the efficacy of selenium supplementation for polycystic ovary syndrome. PubMed, EMbase, Web of science, EBSCO, Cochrane library database, CNKI, Chongqing VIP database and Wanfang databases have been searched through July 2022 and we included randomized controlled trials (RCTs) reporting the effect of selenium supplementation versus placebo in patients with polycystic ovary syndrome. Five RCTs were included in the meta-analysis. Compared with placebo group for polycystic ovary syndrome, selenium supplementation was associated with significantly reduced total testosterone (SMD=-0.42; 95% CI=-0.78 to -0.06;  = 0.02) and cholesterol (SMD=-0.71; 95% CI=-1.41 to -0.02;  = 0.04), but revealed no remarkable influence on SHBG (SMD=-0.52; 95% CI=-1.29 to 0.25;  = 0.19), triglyceride (SMD=-1.45; 95% CI=-3.62 to 0.73;  = 0.19), LDL (SMD=-0.17; 95% CI=-0.72 to 0.37;  = 0.53), FPG (SMD=-0.95; 95% CI=-3.72 to 1.82;  = 0.50) or HOMA-IR (SMD=-0.51; 95% CI=-3.79 to 2.77;  = 0.76). Selenium supplementation may be able to improve the metabolic response for polycystic ovary syndrome, and this finding should be interpreted with caution.